Novo Nordisk A/S Revenue & Financials

Novo Nordisk A/S reported 290.42 billion DKK (approximately $42.7 billion USD at the 2024 average exchange rate) in net sales for FY2024, representing a 25% increase at constant currency compared to FY2023, driven by the explosive commercial scaling of the semaglutide franchise which successfully offset the decline of legacy insulin assets. The company's operating profit surged to 125.3 billion DKK ($18.4 billion), reflecting a highly efficient cost structure that delivered a 43.1% operating margin, one of the highest in the global pharmaceutical industry. Net income reached 97.7 billion DKK ($14.3 billion), while free cash flow generation remained exceptionally strong at 91.2 billion DKK ($13.4 billion), providing the financial flexibility to fund a 34.6 billion DKK R&D budget and execute a massive 28.6 billion DKK capital expenditure program. The FY2024 financial results highlight a company in the midst of a successful portfolio transition. While legacy insulin sales declined by 4% due to biosimilar competition and VBP pricing pressure in China, the combined sales of Ozempic (146.9 billion DKK), Wegovy (68.2 billion DKK), and Rybelsus (2.8 billion DKK) demonstrated that the next generation of incretin therapies is achieving commercial scale faster than anticipated. The company's gross margin remained stable at approximately 84%, reflecting the pricing power of its patented biologics portfolio despite increasing manufacturing costs for complex peptide synthesis and fill-finish operations. Selling, general, and administrative expenses were tightly controlled, growing at a slower rate than revenue, which contributed to the margin expansion. The balance sheet remains fortress-like, with substantial cash reserves and manageable debt levels, allowing Novo Nordisk to maintain a progressive dividend policy while executing a 40 billion DKK share buyback program authorized in 2024. This capital return strategy is designed to support the stock price during the transition period between legacy insulin patents and new GLP-1 launches, signaling management's confidence in the long-term cash generation capabilities of the incretin-focused model. The FY2024 financial performance validates the strategic decision to pivot aggressively toward obesity therapeutics, as the removal of the low-margin legacy insulin focus has significantly improved the company's overall profitability metrics and return on invested capital. The detailed breakdown of the FY2024 income statement reveals the underlying drivers of this financial success. Net sales of 290.42 billion DKK were composed of 188.5 billion DKK from the US market, 58.2 billion DKK from Europe, 28.4 billion DKK from China, and 15.3 billion DKK from the rest of the world. The US market remains the most profitable region, contributing approximately 65% of total revenue but an even higher percentage of operating profit due to the significantly higher pricing power for innovative biologics in the United States compared to Europe and Asia. The cost of goods sold (COGS) was 46.2 billion DKK, resulting in a gross profit of 244.2 billion DKK and a gross margin of 84.1%. This high gross margin is characteristic of the innovative biologics industry and reflects the relatively low marginal cost of manufacturing peptide therapies once the initial capital-intensive fermentation facilities have been built and the regulatory approvals have been obtained. Research and development expenses totaled 34.6 billion DKK, representing 11.9% of net sales. This substantial R&D investment is critical for maintaining the company's competitive position and driving future growth, and it is allocated across a diverse portfolio of early-stage discovery programs, Phase I and II clinical trials, and large-scale Phase III registrational studies like the SELECT and FLOW trials. Selling, general, and administrative (SG&A) expenses were 73.5 billion DKK, or 25.3% of net sales, reflecting the significant commercial investment required to launch and support the company's growing portfolio of GLP-1 therapies and navigate the complex PBM rebate landscape. The operating profit of 125.3 billion DKK was achieved after deducting amortization of intangible assets of 1.8 billion DKK and other operating income/expenses of 0.6 billion DKK, resulting in an operating margin of 43.1%. This exceptional margin performance is a testament to the company's rigorous cost management practices and the high operating leverage inherent in the innovative biologics business model. The net income of 97.7 billion DKK was achieved after deducting income taxes of 27.6 billion DKK, resulting in an effective tax rate of 22.0%, which is slightly below the statutory Danish rate due to the favorable geographic mix of the company's profits and the utilization of various tax credits and incentives. The strong cash flow generation of 91.2 billion DKK provided the company with the financial flexibility to return 35.4 billion DKK to shareholders through dividends and share buybacks, while also funding 28.6 billion DKK in strategic capital expenditures and 12.5 billion DKK in business acquisitions. The balance sheet at the end of FY2024 showed total assets of 412.5 billion DKK, total liabilities of 245.3 billion DKK, and total equity of 167.2 billion DKK, resulting in a debt-to-equity ratio of 0.65, which is well within the company's target range and provides a strong foundation for future growth and capital allocation initiatives.